{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal ExoFlo",
            "NStudiesAvail": 430108,
            "NStudiesFound": 9,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 9,
            "FieldList": [
                  "OverallOfficialName",
                  "OverallOfficialRole",
                  "OverallStatus",
                  "OversightHasDMC",
                  "PatientRegistry",
                  "Phase",
                  "PointOfContactEMail",
                  "PointOfContactOrganization",
                  "PointOfContactPhone",
                  "PointOfContactPhoneExt",
                  "PointOfContactTitle",
                  "PrimaryCompletionDate",
                  "PrimaryCompletionDateType",
                  "PrimaryOutcomeDescription",
                  "PrimaryOutcomeMeasure",
                  "NCTId"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [
                              "The incidence of serious adverse events.",
                              "Number to patients with All-Cause Mortality at 28 days"
                        ],
                        "NCTId": [
                              "NCT05127122"
                        ]
                  },
                  {
                        "Rank": 2,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 1, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "\u2022 To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.",
                              "To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\n\nTo evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\nTo evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\nTo evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.\nTo evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "\u2022 To evaluate the feasibility of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies.",
                              "\u2022 To evaluate the safety of intravenous ExoFlo in subjects with moderately to severely active Crohn's disease who have failed or are intolerant to one or more monoclonal antibodies."
                        ],
                        "NCTId": [
                              "NCT05130983"
                        ]
                  },
                  {
                        "Rank": 3,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "March 7, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Change in SARS-CoV-2 log viral load from baseline to Day=7"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Change in SARS-CoV-2 log viral load from baseline to Day=7"
                        ],
                        "NCTId": [
                              "NCT05125562"
                        ]
                  },
                  {
                        "Rank": 4,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "January 1, 2024"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
                              "Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of subjects who tolerate intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies.",
                              "Number of adverse events in subjects who received intravenous ExoFlo in those subjects with moderately to severely active Ulcerative colitis who have failed or are intolerant to one or more monoclonal antibodies."
                        ],
                        "NCTId": [
                              "NCT05176366"
                        ]
                  },
                  {
                        "Rank": 5,
                        "OverallOfficialName": [],
                        "OverallOfficialRole": [],
                        "OverallStatus": [
                              "Available"
                        ],
                        "OversightHasDMC": [],
                        "PatientRegistry": [],
                        "Phase": [],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [],
                        "PrimaryCompletionDateType": [],
                        "PrimaryOutcomeDescription": [],
                        "PrimaryOutcomeMeasure": [],
                        "NCTId": [
                              "NCT04657458"
                        ]
                  },
                  {
                        "Rank": 6,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 1",
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "February 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Meters walked in a self-paced test in which the subject is instructed to walk as fast as possible during 6 minutes.",
                              "Rate of SAEs observed over the duration of the study."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Increased distance on Six Minute Walk Test (6MWT)",
                              "Incidence of Serious Adverse Events (SAEs)"
                        ],
                        "NCTId": [
                              "NCT05116761"
                        ]
                  },
                  {
                        "Rank": 7,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 3"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "April 3, 2023"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "The primary efficacy endpoint is overall 60-day mortality (due to any cause)."
                        ],
                        "PrimaryOutcomeMeasure": [
                              "The primary efficacy endpoint is overall 60-day mortality (due to any cause)."
                        ],
                        "NCTId": [
                              "NCT05354141"
                        ]
                  },
                  {
                        "Rank": 8,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Principal Investigator"
                        ],
                        "OverallStatus": [
                              "Not yet recruiting"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Early Phase 1"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "October 2022"
                        ],
                        "PrimaryCompletionDateType": [
                              "Anticipated"
                        ],
                        "PrimaryOutcomeDescription": [
                              "20 patients who meet the criteria for Expanded Access as determined by the principal investigator and who do not otherwise qualify for an available clinical trial"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "Number of participants with adverse/serious adverse events"
                        ],
                        "NCTId": [
                              "NCT05215288"
                        ]
                  },
                  {
                        "Rank": 9,
                        "OverallOfficialName": [
                              "Vikram Sengupta, MD"
                        ],
                        "OverallOfficialRole": [
                              "Study Chair"
                        ],
                        "OverallStatus": [
                              "Completed"
                        ],
                        "OversightHasDMC": [
                              "Yes"
                        ],
                        "PatientRegistry": [],
                        "Phase": [
                              "Phase 2"
                        ],
                        "PointOfContactEMail": [],
                        "PointOfContactOrganization": [],
                        "PointOfContactPhone": [],
                        "PointOfContactPhoneExt": [],
                        "PointOfContactTitle": [],
                        "PrimaryCompletionDate": [
                              "May 1, 2021"
                        ],
                        "PrimaryCompletionDateType": [
                              "Actual"
                        ],
                        "PrimaryOutcomeDescription": [
                              "Efficacy Endpoint; PaO2/FiO2 ratio"
                        ],
                        "PrimaryOutcomeMeasure": [
                              "7 Day Change in Partial Pressure of Arterial Oxygen to Fraction of Inspired Oxygen Ratio"
                        ],
                        "NCTId": [
                              "NCT04493242"
                        ]
                  }
            ]
      }
}